TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research[1].
TJ191(0-100 μM; 24 hours) exhibits pronounced anti-proliferative activity in malignant cell lines, the IC50 values are 0.13 μM, 0.13±0.08 μM, 0.26±0.19 μM, 0.22±0.11 μM, 1.5±0.02 μM, 0.32±0.086 μM, 3.1±0.5 μM, 0.26±0.16 μM in CEM, JURKAT, MOLT-3, MOLT-4, SUP-T1, MT-2, C8166 and HSB-2 cells, respectively. But has no effects in HUT-78 (IC50=17±10 μM) and MT-4 (IC50=47 ± 5 μM) cells[1].TJ191 (0.1-3 μM; 8 or 24 hours) induces CEM cell apoptosis in a concentration- and time-dependent manner. Even at 0.3 μM, TJ191 induces the maximum apoptotic rate of 80% after 24 h[1].
[1]. Ahmed El-Gazzar, et al. 2-Amino-3-methylcarboxy-5-heptyl-thiophene (TJ191) is a selective anti-cancer small molecule that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. Oncotarget. 2017 Dec 15;9(5):6259-6269.
